Home > Boards > US Listed > Biotechs > OncoCyte (OCX)

Oncocyte Announces Final Medicare LCD from Palmetto for

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Big Barnie Member Profile
Followed By 2
Posts 893
Boards Moderated 1
Alias Born 07/11/13
160x600 placeholder
Oncocyte in pact with Echelon Diagnostics to support commercial expansion of tests Seeking Alpha - 6/15/2021 8:28:40 AM
OncoCyte signs an at-the-market agreement to sell $50M of common stock Seeking Alpha - 6/14/2021 7:07:24 AM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 6/14/2021 6:01:56 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2021 6:01:55 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 6/9/2021 6:04:57 AM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 6/1/2021 4:26:19 PM
Securities Registration Statement (simplified Form) (s-3) Edgar (US Regulatory) - 5/28/2021 5:07:30 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 5/24/2021 7:20:19 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 5/21/2021 4:11:03 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 5/21/2021 4:06:17 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/21/2021 8:01:17 AM
VRNA, PDD, IOVA and PRVB among after-hours movers Seeking Alpha - 5/18/2021 5:42:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/17/2021 5:19:44 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/17/2021 4:11:13 PM
OncoCyte EPS beats by $0.05, beats on revenue Seeking Alpha - 5/17/2021 4:01:58 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 5/10/2021 8:00:52 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/30/2021 7:09:54 PM
Amended Annual Report (10-k/a) Edgar (US Regulatory) - 4/30/2021 8:30:55 AM
Oncocyte’s DetermaIO shows correlation with immunotherapy response in bladder cancer Seeking Alpha - 4/10/2021 9:48:30 PM
Oncocyte CEO discloses insider buying Seeking Alpha - 3/24/2021 6:40:43 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 3/16/2021 4:37:00 PM
OncoCyte EPS beats by $0.02, misses on revenue Seeking Alpha - 3/16/2021 4:06:03 PM
Big Barnie   Friday, 05/01/20 05:45:12 AM
Re: None
Post # of 125 
Oncocyte Announces Final Medicare LCD from Palmetto for DetermaRx™

May lead to Medicare coverage for up to 70% of eligible early-stage lung cancer patients
Email Print Friendly Share
April 30, 2020 14:21 ET | Source: OncoCyte Corporation
IRVINE, Calif., April 30, 2020 (GLOBE NEWSWIRE) -- Oncocyte Corporation (NYSE American: OCX), a molecular diagnostics company with a mission to provide actionable answers at critical decision points across the cancer care continuum, today announced that Palmetto, the Medicare Administrative Contractor for the Centers for Medicare & Medicaid Services (CMS), has issued a final local coverage decision for DetermaRx™. The test, which launched earlier this year via an early access program, is the first and only predictive test for the identification of patients with Stage I-IIA non-squamous NSCLC who are at high-risk for recurrence following surgery and are likely responsive to adjuvant chemotherapy.
“Today’s CMS decision is a significant milestone for Oncocyte. Not only can we now increase outreach to more patients and physicians around the country, but we believe several national and regional payers will follow this decision, giving additional patients insurance coverage for this important test,” said Ron Andrews, CEO of Oncocyte. “The DetermaRx test addresses a critical unmet need for the 30-50% of patients with early-stage lung cancer who have a recurrence despite having “curative” surgery. In a published clinical study, patients identified as high-risk by the DetermaRx test post-surgery and treated by chemotherapy had survival rate of 92% compared to high-risk untreated patients who had a survival rate of 49%.”
“Despite the impact of COVID-19, we have seen significant interest in this test just in the first quarter of launch, with twenty onboarded sites and more than 1500 attendees to physician education programs. Today’s CMS decision further supports the promise of DetermaRx, and we are looking forward to expanding our reach throughout the U.S. over the coming months.”
Following this decision, Oncocyte intends to intensify its efforts with private payers who have a history of following Medicare coverage decisions, with the goal of securing coverage for patients with private insurance.
Please visit CMS.gov to view the final local coverage decision memo.
About Oncocyte Corporation
Oncocyte is a molecular diagnostics company whose mission is to provide actionable answers at critical decision points across the cancer care continuum, with the goal of improving patient outcomes by accelerating and optimizing diagnosis and treatment. The Company recently launched DetermaRx™, a treatment stratification test that enables the identification of early-stage lung cancer patients at high risk for recurrence post-resection, allowing them to be treated when their cancer may be more responsive to adjuvant chemotherapy. DetermaDx™, the company’s liquid biopsy test in development, utilizes a proprietary immune system interrogation approach to clarify if a patients’ lung nodules are benign, which may enable them to avoid potentially risky invasive diagnostic procedures. Oncocyte is also developing DetermaIO™, a gene expression test that identifies patients more likely to respond to checkpoint immunotherapies. DetermaDx, DetermaRx and DetermaIO are trademarks of Oncocyte Corporation.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences